Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of the present study is to investigate whether orally (lingual spray) administered oxytocin influences human top-down attention via oxytocin receptors and whether its effects are dose- and task-dependent.
In a placebo-controlled double-blind between-subject design experiment, investigators plan to investigate whether oral (lingual spray) oxytocin influences human top-down attention via the oxytocin receptor and whether its effects are dose- and task-dependent. Subjects complete questionnaires in Chinese versions before treatment administration, including Behavioral Activation System scale, Behavioral Inhibition System scale,Trait Anxiety Inventory, State Anxiety Inventory, Liebowitz Social Anxiety Scale, Beck Depression Inventory, Autism Spectrum Quotient. Then the first blood (6ml via indwelling medial cubital vein catheter) and saliva (1-2 ml, passive drool) samples are collected, followed by the first self-administered medication (three sublingual and three supragingival administrations, alternating separated by 30 seconds). After a 15-minute interval, the second medication is administered, with a second blood sample collected immediately afterwards. Subjects then remain in the lab for 30 minutes (mobile phone use and conversation with experimenters are prohibited during this period). Behavioral experiment (antisaccade) commences after the third blood collection. During these phases, subjects' latency of correct trials, error rate and pupil size in response to stimuli will be measured using eye tracking equipment. Immediately after completion of the paradigm subjects will complete the state anxiety questionnaire again to assess treatment/paradigm effects on anxiety.
A Mixed linear model, followed by appropriate post-hoc analyses will be used on eye-tracking and other data to assess treatment effects. Correlation analysis will be used to assess associations between latency of correct trials in prosaccade and error rate in antisaccade in the different groups. Investigators make the following hypotheses according to our previous studies: first, oral oxytocin treatment will dose-dependently decrease top-down attention to social but also non-social stimuli; secondly, oxytocin concentrations will be dependent on the dose of oral administration and will not be influenced by oral administration of the oxytocin receptor antagonist (atosiban) administration; thirdly, atosiban is anticipated to have the opposite effect of oral oxytocin and may not interfere with top-down attention; fourthly, oxytocin treatment will increase pupil diameter while viewing social stimuli; fifthly, there will be treatment- dependent effects on post-task state anxiety scores; lastly, antisaccade performance in each group might be influenced by subjects' scores on autistic traits.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oxtocin 24IU group | Experimental | Interventions are placebo followed after 15 minutes by the lower does (24IU) oxytocin |
|
| atosiban group | Experimental | Interventions are placebo followed after 15 minutes by 150ug atosiban |
|
| placebo group | Placebo Comparator | Interventions are placebo followed after 15 minutes by another placebo |
|
| Oxytocin 48IU group | Experimental | Interventions are placebo followed after 15 minutes by the higher 48IU oxytocin does |
|
| Atosiban and 24IU oxytocin group | Experimental | Interventions are atosiban 150ug followed after 15 minutes by the lower (24IU) does of oxytocin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oxytocin lower does (24IU) | Drug | Oxytocin (24IU) will be administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Error rates in prosaccade and antisaccade trials | Error rates in prosaccade and antisaccade using eye- tracking technique | Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data on numbers of prosaccade and antisaccade errors being collected continuously over a period of 35 minutes. |
| Responses latencies for prosaccades and antisaccades | response latencies for correct first saccades will be measured on each prosaccade or antisaccade trial using eye-tracking | Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data on prosaccade and antisaccade response times taken continuously during the 35 minute task |
| Measure | Description | Time Frame |
|---|---|---|
| Oxytocin concentration | OT concentrations will be measured in blood (plasma) samples (6ml) taken from indwelling catheter in median cubital vein and saliva samples (1-2ml) taken using passive drool. OT concentrations will be measured using appropriate essays. | On the day of the experiment blood and saliva samples will be taken at time 0 (baseline) immediately prior to the first treatment, a 2nd sample will be taken at 15 minutes and a 3rd sample at 45 minutes post-treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Healthy male subjects without past or current psychiatric or neurological disorders
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Keith M Kendrick, PhD | Contact | +86-28-61830811 | k.kendrick.uestc@gmail.com | |
| Yige Wang, PhD | Contact | +86-13086688860 |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| School of Life science and Technology, University of Electronic Science and Technology of China | Recruiting | Chengdu | Sichuan | China |
Participant data will be shared with other qualified researchers upon request
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C047046 | atosiban |
Not provided
Not provided
Not provided
Randomized placebo-controlled double-blind between-subject design experiment including 5 treatment groups receiving oral oxytocin, atosiban, or placebo interventions prior to performing antisaccade task.
Not provided
Not provided
Not provided
| Oxytocin higher does (48IU) | Drug | Oxytocin (48IU) will be administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on and under the tongue) |
|
| Atosiban | Drug | 150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue) |
|
| Placebo | Drug | Placebo administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue). Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and the atosiban interventions. |
|
| Pupil size | Pupil size will be measured during antisaccade task using eye-tracker | Starting 45 minutes post-treatment continuous eye-tracking will be used to measure changes in pupil size during the whole of the 35 minute antisaccade task |
| State anxiety | State anxiety will be measured using a questionnaire (40 self-report question-state-trait-anxiety inventory, with total scores ranging from 20-80, where higher scores indicate greater anxiety). | On the day of the experiment subjects will complete the questionnaire immediately prior to treatment at time 0 (baseline) and again 75 minutes post-treatment after completion of the antisaccade task |
| Correlation between prosaccade latency and antisaccade errors | The correlation between two of the primary outcome measures (prosaccade latencies and antisaccade errors) taken during trials will be analyzed using the Spearman correlation test for each treatment group. Differences between correlations in the groups will be assessed using Fisher's z tests | Starting 45 minutes post-treatment subjects will complete the eye-tracking task with data being collected continuously over a 35 minute period |